“GLP-1 analogues are reshaping diabetes and obesity care as innovation in drug delivery, expanding indications, and strong R&D pipelines drive explosive global demand.” Boston, Jan. 30, 2026 (GLOBE ...
MedPage Today on MSN
New Kink in the Link Between GLP-1 Drugs and Cognition
By extending survival, GLP-1 agents may expand the dementia risk period for diabetes patie ...
For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently so ...
GLP-1 drugs like Wegovy alone do not work, may benefit more from a combination treatment, a recent review of the evidence ...
MetaVia begins patient dosing in Part 3 of phase 1 study of DA-1726, a GLP-1 and glucagon dual agonist to treat obesity: Cambridge, Massachusetts Monday, April 13, 2026, 11:00 Hrs ...
The Drugs Consultative Committee (DCC), during its 68th meeting, deliberated on strengthening regulatory oversight and ...
Researchers map the peptide behind semaglutide across 25 brain regions in each sex, finding striking differences in appetite and reward circuits. GLP-1 analogs, used to treat obesity, are among the ...
Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ ...
Oklahoma researchers found the hormone FGF21 targets the same brain region as GLP-1 drugs, but works by boosting metabolic ...
Though they've been around for a while, GLP-1 drugs – also called GLP-1 agonists, incretin mimetics, or GLP-1 analogs – have recently gotten more popular as medications that can help you manage your ...
The Chosun Ilbo on MSN
GLP-1 hormone in joints may directly ease arthritis
A research team from Aarhus University in Denmark has confirmed for the first time that the hormone GLP-1, used in obesity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results